TY - JOUR
T1 - Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
AU - Kurozumi, Kazuhiko
AU - Fujii, Kentaro
AU - Washio, Kana
AU - Ishida, Joji
AU - Otani, Yoshihiro
AU - Sudo, Tamotsu
AU - Tahara, Makoto
AU - Ichimura, Koichi
AU - Ennishi, Daisuke
AU - Date, Isao
N1 - Publisher Copyright:
© The Author(s), 2022.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.
AB - Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=85134933963&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134933963&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdac094
DO - 10.1093/noajnl/vdac094
M3 - Article
AN - SCOPUS:85134933963
SN - 2632-2498
VL - 4
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdac094
ER -
